699855P

3D-(6-acyl) PHAD^™

Avanti Research^™ - A Croda Brand

• Synonim(y): Monophosphoryl Hexa-acyl Lipid A, 3-Deacyl (Synthetic)
• Wzór empiryczny (zapis Hilla): C₉₆H₁₈₄N₃O₂₁P
• Numer CAS: 252042-59-4
• Masa cząsteczkowa: 1747.47
• Kod UNSPSC: 12352211
• NACRES: NA.25

Właściwości

• Próba: >99% (HPLC)
• Formularz: powder
• opakowanie: pkg of 1 × 1 mg (699855P-1mg); pkg of 1 × 10 mg (699855P-10MG); pkg of 1 × 10 mg (699855P-25MG); pkg of 1 × 5 mg (699855P-5mg)
• producent / nazwa handlowa: Avanti Research^™ - A Croda Brand
• Zastosowanie: vaccine development
• Warunki transportu: dry ice
• temp. przechowywania: −20°C
• ciąg SMILES: O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
• InChI: 1S/C96H181N2O21P.H3N/c1-7-13-19-25-31-37-40-46-52-58-64-70-85(102)113-78(67-61-55-49-43-34-28-22-16-10-4)73-83(100)97-89-92(107)91(106)82(116-95(89)108)77-112-96-90(98-84(101)74-79(68-62-56-50-44-35-29-23-17-11-5)114-86(103)71-65-59-53-47-41-38-32-26-20-1
• Klucz InChI: BKGJOWVNLQLVQX-ZLHZNJIMSA-N

Opis

Opis ogólny

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD^™), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Zastosowanie

3D-(6-acyl) PHAD^™ has been used:

• as a synthetic adjuvant in human papillomavirus (HPV) and virus-like particles (VLPs)-based HPV vaccine preparations[1]
• as a component of liposomes for immunizing mice with P. falciparum (Pfs25) malaria transmission-blocking vaccine antigen candidate[2]
• in liposome preparation for the generation of army liposome formulation (ALF) for human immunodeficiency (HIV) gp140 antigen immunization studies in mice[3]

Opakowanie

Fiolka z zakrętką z bursztynowego szkła o pojemności 5 ml (699855P-10MG); Fiolka z zakrętką z bursztynowego szkła o pojemności 5 ml (699855P-25MG)

2 mL Amber Glass Crimp Cap Vial (699855P-1mg)

2 mL Amber Glass Crimp Cap Vial (699855P-5mg)

Inne uwagi

For R&D use only. Not for drug, household, or other uses.

Informacje prawne

Avanti Research is a trademark of Avanti Polar Lipids, LLC

PHAD is a trademark of Avanti Polar Lipids, LLC

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Kod klasy składowania: 11 - Combustible Solids
• Klasa zagrożenia wodnego (WGK): WGK 3
• Temperatura zapłonu (°F): No data available
• Temperatura zapłonu (°C): No data available